KalVista Pharmaceuticals, Inc.
NASDAQ:KALVBiotechnology
+$0.00 today
- Market cap
- $1.44B
- Beta
- -0.11
- P/E (TTM)
- -9.9
- EPS (TTM)
- -$2.74
Volume 4.26M
Average 3.47M
KALV Short-term Debt
Borrowings and the current portion of long-term debt due within one year.
KalVista Pharmaceuticals, Inc.NASDAQ: KALV
Short-term Debt · Q4 FY2026 · quarter ended Dec 2025
Short-term debt of $0 in Q4 FY2026
Q4 FY2026 short-term debt was $0.
Context
- Short-term debt amounted to 0.0% of total assets at the end of Q4 FY2026.
- Short-term debt increased in 0 of the last 3 fiscal years.
- FY2026 was the highest annual figure in the 4 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Short-term Debt history
USD · from the balance sheet
- Latest · FY2026
- 0 USD
- Year-over-year change
- —
| Period | Period end | Short-term Debt | YoY change |
|---|---|---|---|
| FY2026 | 2025-12-31 | 0 | — |
| FY2025 | 2025-04-30 | 0 | — |
| FY2024 | 2024-04-30 | 0 | — |
| FY2023 | 2023-04-30 | 0 | — |
| FY2022 | 2022-04-30 | 0 | — |
Short-term Debt vs competitors
How KALV compares with its peers on the latest reported figures
- KALV's Dec 2025 short-term debt of $0 is the 7th highest of the 10 companies compared; the peer median is $957K.
- Short-term debt amounts to 0.0% of total assets for KALV, versus a peer median of 0.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $30.5M | +105.9% | — | 6.0% | |
| Mar 2026 | $26.27M | -45.3% | -43.5% | 9.2% | |
| Mar 2026 | $5.8M | +188.3% | +24.8% | 2.5% | |
| Mar 2026 | $4.64M | — | -37.8% | 1.6% | |
| Mar 2026 | $957K | — | — | 0.7% | |
| Mar 2026 | $956K | — | — | 0.2% | |
| Dec 2025 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | — | — | 0.0% | |
| Mar 2026 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding KALV) | $957K | +30.3% | -37.8% | 0.7% | |
Competitors are the stored peer set for KALV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Apr 2022 | FY2023 Apr 2023 | FY2024 Apr 2024 | FY2025 Apr 2025 | FY2026 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 30.73M | 56.24M | 31.79M | 98.64M | 229.34M |
| Short-term Investments | 135.47M | 93.14M | 178.61M | 89M | 70.87M |
| Net Receivables | 16.81M | 18.64M | 10.87M | 15.14M | 11.3M |
| Inventory | 0 | 0 | 0 | 0 | 3.43M |
| Other Current Assets | 0 | 0 | 0 | 19.21M | 0 |
| Total Current Assets | 193.65M | 172.33M | 225.69M | 241.69M | 320.15M |
| Property, Plant & Equipment (Net) | 10.04M | 10.77M | 9.15M | 1.99M | 12.86M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 193K | 106K | 567K | 7.09M | 2.37M |
| Total Non-current Assets | 10.23M | 10.88M | 9.71M | 9.08M | 15.23M |
| Total Assets | 203.88M | 183.2M | 235.4M | 250.77M | 335.38M |
| Account Payables | 3.64M | 4.82M | 9.11M | 4.88M | 8.27M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 11M | 0 |
| Other Current Liabilities | 4.17M | 4.21M | 6.69M | 0 | 36.8M |
| Total Current Liabilities | 11.58M | 15.03M | 22.81M | 45.17M | 57.36M |
| Long-term Debt | 0 | 0 | 0 | 0 | 139.23M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 105.88M | 11.71M |
| Other Non-current Liabilities | 0 | 0 | 0 | 0 | 119.06M |
| Total Non-current Liabilities | 7.21M | 7.15M | 6.02M | 110.21M | 280.73M |
| Total Liabilities | 18.79M | 22.18M | 28.82M | 155.38M | 338.09M |
| Common Stock | 25K | 34K | 42K | 50K | 51K |
| Retained Earnings | (250.18M) | (343.08M) | (469.73M) | (653.17M) | (762.69M) |
| Accumulated OCI | (3.86M) | (3.06M) | (3.49M) | (5.21M) | (7.13M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 185.09M | 161.03M | 206.58M | 95.39M | (2.71M) |
| Total Debt | 8.19M | 8.23M | 7.32M | 6.31M | 151.58M |
| Net Debt | (22.54M) | (48.01M) | (24.47M) | (92.34M) | (77.77M) |
KalVista Pharmaceuticals, Inc.
NASDAQ:KALV
Intrinsic Alpha fair value
Locked
Current Price
$27.00
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.